Neurogene Inc.

NASDAQ:NGNE

Biotechnology

Healthcare
$23.10 +2.47%

+$0.76 today

Market cap
$365.03M
Beta
2.04
P/E (TTM)
-7.1
EPS (TTM)
-$4.42
52W Low $14.65High $37.27

Volume 0.28M

Average 0.16M

Returns on capital

Neurogene Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-34.1%

avg -25.9%

ROIC

-37.5%

avg -33.3%

ROA

-31.3%

avg -33.0%

Analysis

ROA is currently the strongest return metric at -31.3% versus its period average of -33.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Rachel L. McMinn

Founder, Executive Chair & Chief Executive OfficerUSD 997.24K53——

Christine Mikail Cvijic

President, CFO & DirectorUSD 874.06K4884.04K0.53%

Julie Jordan

Chief Medical OfficerUSD 696.34K5412.47K0.08%

Stuart Cobb

Chief Scientific OfficerUSD 478.81K5530.50K0.19%

Arvind Sreedharan

Senior Vice President of Business Operations————

Christina Shafer

Chief Commercial Officer—50120.00K0.76%

Lina Li

Executive Director of Investor Relations————

Andrew E. Mulberg FAAP

Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control————

Donna Cochener-Metcalfe

Senior Vice President, General Counsel & Corporate Secretary—51——

Ricardo Jimenez

Senior Vice President of Technical Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 7, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

17

$1.13M

Net Transaction Value

−$1.13M

Net selling

Most Active

Cvijic Christine Mikail

12 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 7, 26

Cvijic Christine Mikail

Direct

Sell$151.8K
Jul 6, 26

Cvijic Christine Mikail

Direct

Sell$21.6K
Jul 2, 26

Cvijic Christine Mikail

Direct

Sell$87.5K
Jul 2, 26

Cvijic Christine Mikail

Direct

Sell$53.9K
Jul 1, 26

Cvijic Christine Mikail

Direct

Sell$25.2K
May 6, 26

Cvijic Christine Mikail

Direct

Sell$144.4K
May 6, 26

Cvijic Christine Mikail

Direct

Sell$155.7K
Mar 26, 26

Cvijic Christine Mikail

Direct

Sell$55.3K
Mar 26, 26

McMinn Rachel

Direct

Sell$74K
Mar 26, 26

Jordan Julie

Direct

Sell$18.1K

1–10 of 17

Summary

Insiders reported 0 buys worth $0.00 and 17 sells worth $1.13M over the last 12 months. That adds up to net selling of $1.13M. Cvijic Christine Mikail was the most active insider with 12 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
N/A5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Neurogene Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about NGNE's management, answered from reported figures.

Who manages NGNE?

Neurogene Inc. (NGNE) lists 10 active executives. The top listed executive is Stuart Cobb, Chief Scientific Officer.

Are NGNE insiders buying or selling?

Recent insider activity shows net buying of $27.81M.